Table 1.
The role of Cav1 in breast cancer cells tumorigenesis
Progress stages | Cell lines | Signaling cascades | Promoter/suppressor | References |
---|---|---|---|---|
Proliferation, invasion | MCF-7 | Cav1↑ → BKCa↓ | Suppressor | 46 |
Proliferation | SKBR3 BT-474 | γ-tocotrienol → caveolae disruption → HER2 signaling↓ | Promoter | 49 |
Proliferation, invasion, migration | BT-474 | Cav1↑ → cell cycle arrest↓ Cav1↓ → MMP-2, MMP-9, MMP-1↓ |
Promoter | 50 |
Proliferation | MDA-MB-231 MCF-7 | Cav1↑ → cell cycle arrest↑ | Suppressor | 51 |
Proliferation | MDA-MB-231 | BPA → Cav1-GPER↑ → HSP90, HIF-1α, VEGF↑ | Promoter | 52, 58 |
Proliferation | BT-474 | CAFs Cav1↓ → SDF–1, EGF, FSP–1↑ | Suppressor | 59 |
Apoptosis | MDA-MB-231 MDA-MB-468 | MβCD → Cav1↓ → apoptotic pathways↑ | Promoter | 65 |
Apoptosis | MDA-MB-231 MCF-7 | Cav1↑ → apoptotic pathways↑ | Suppressor | 51 |
Autophagy | BT-474 | E2 → Cav1↑ → autophagosome↑ | Promoter | 66 |
Autophagy | MCF-7 | Cav1↓ → V-ATPase assembly↑ → autophagosome− lysosome fusion↑ | Suppressor | 67 |
Apoptosis | MCF-7 | Fluvastatin → CAV1 mRNA expression↓ | Promoter | 68 |
Apoptosis | MCF-7 | Metformin → CAV1 mRNA expression↑ | Suppressor | 69 |
Apoptosis | MDA-MB-231 SK-BR-3 | DHA → Cav1↑ → onco-proteins, HSP90↓ | Suppressor | 70 |
Invasion, migration | MCF-7 T47D | Cav1↑ → Slug↑ → EMT↑ | Promoter | 81 |
Invasion, migration | MDA-MB-231 4T1 | FFLZ → Cav-1/Smad7/Smurf2↓ → TGFR signaling↓ → EMT↓ | Promoter | 82 |
Invasion, migration | MCF-10F | Curcumin, pamidronate → Cav1↓ → EMT↓ | Promoter | 83, 84 |
Invasion | MCF-7 | Antarctic krill DHA → Cav1-Fas↑ → MMP-2↓ | Suppressor | 86 |
Migration | MDA-MB-231 MCF-7 | ROS → Cav1-GAP↓ | Promoter | 90 |
Invasion, migration | MDA-MB-231 | Cav1↑ → Rab5↑ → Rac1↑ | Promoter | 91 |
Anoikis | MDA-MB-231 | LSS → Cav1↑ → caspase-8↓ → anoikis↓ | Promoter | 101 |
Anoikis | MDA-MB-231 | Cav1↑ → ITGB1-FAK↑ → anoikis↓ | Promoter | 102 |
Metastasis | MDA-MB-231 | Cav1↑ → MT4-MMP recycling↑ | Promoter | 104 |
Metastasis | E0771 | Cav1↓ → VEGF-A/VEGFR1↑ → MMP9, CSF1↑ | Suppressor | 105 |
Metastasis | MDA-MB-231 MCF-7 T47D | MIF → Cav1 phosphorylation↑ → HMGB1↑ → TLR4/NF-kappa B↑ | Promoter | 106 |
Drug resistance | MCF-7 MDA-MB-231 | Cav1↑ → ABCG2↑ → drug resistance↑ | Promoter | 114 |
Drug resistance | BT-474 | Cav1↑ → T-DM1 internalization↑ | Suppressor | 121 |
Drug resistance | MCF-7 | Cav1↑ → eNOS/NO/ONOO-↓ | Promoter | 124 |
Radiation resistance | BT474 SKBR3 MDA-MB-231 | Cav1↑ → EGFR nuclear translocation↑ → DNA repair↑ | Promoter | 126 |
Abbreviations: ABCG2, ATP-binding cassette subfamily G member 2; BKCa, large conductance Ca2+-activated potassium; BPA, Bisphenol A; CAFs, cancer-associated fibroblasts; Cav1, caveolin-1; CSF1, colony-stimulating factor 1; DHA, docosahexaenoic acid; EMT, epithelial to mesenchymal transition; FAK, focal adhesion associated kinases; FFLZ, fucose-containing fraction of Ling-Zhi; FSP-1, fibroblast-specific protein-1; GAP, GTPase-activating protein; GPER, G-protein estrogen receptor; HER2, human epidermal growth factor receptor-2; HIF-1α, hypoxia inducible factor-1 alpha; HSP90, heat shock protein 90; LSS, fluid-induced low shear stress; MIF, migration inhibitory factor; MMP, matrix metalloproteinase; MT4-MMP, membrane type 4 matrix metalloproteinase; MβCD, methyl beta cyclodextrin; SDF-1, stromal cell-derived factor-1; T-DM1, trastuzumab emtansine; TGFR, transforming growth factor-β receptor; VEGF, vascular endothelial growth factor.